Hasford et al developed a simple score for evaluating the outcome of a patient with chronic myelogenous leukemia (CML) treated with imatinib. This can help to identify a patient who may benefit from more aggressive or a more novel therapy. The authors are from multiple hospitals in Europe and participants in the European Treatment and Outcome Study for CML (EUTOS).